ASPIRE, 2015 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of carfilzomib versus placebo (on top lenalidomide and dexamethasone) in patients with relapsed multiple myeloma

        Z

NCT01080391    Br J Haematol 2017;:  



Studied treatment carfilzomib with lenalidomide and dexamethasone
Control treatment lenalidomide and dexamethasone alone



Patients patients with relapsed multiple myeloma
Group sizes396 / 396
PFS definition



Blindness open-label Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint PFS Design Parallel groups



EndpointX1N1X0N0TE95% CI OS - -9 - -9 0,79[0,63; 0,99] PFS - -9 - -9 no data0,22,01,0

Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Ma Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015 Jan 8;372:142-52     [PMID: 25482145]   link to pdf   add to Mendeley  

Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizk Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol 2017;:     [PMID: 28211560]   link to pdf   add to Mendeley  

Links

press release

ClinicalTrial.gov record NCT01080391



Registering number NCT01080391 (see trial on clinicaltrials.gov)
Code Name

 

All trials of carfilzomib

Appears in following systematic reviews: